Charles Schwab Investment Management Inc. raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 10.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 255,277 shares of the company's stock after buying an additional 24,043 shares during the period. Charles Schwab Investment Management Inc. owned about 0.54% of Enliven Therapeutics worth $6,520,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ELVN. Quest Partners LLC boosted its position in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock worth $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock valued at $232,000 after purchasing an additional 3,559 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics in the third quarter valued at approximately $256,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Enliven Therapeutics in the second quarter valued at approximately $322,000. Finally, American Century Companies Inc. grew its position in shares of Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company's stock valued at $646,000 after purchasing an additional 8,540 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Robert W. Baird upped their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a research report on Friday, November 15th.
Get Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Price Performance
ELVN traded down $1.28 during trading hours on Thursday, reaching $22.80. The company's stock had a trading volume of 146,853 shares, compared to its average volume of 253,476. Enliven Therapeutics, Inc. has a fifty-two week low of $10.05 and a fifty-two week high of $30.03. The stock has a market cap of $1.11 billion, a PE ratio of -11.61 and a beta of 1.02. The business's 50-day moving average is $26.70 and its 200-day moving average is $24.17.
Insiders Place Their Bets
In related news, CFO Benjamin Hohl sold 5,250 shares of the business's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $24.89, for a total value of $130,672.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Joseph P. Lyssikatos sold 847 shares of the business's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $30.00, for a total value of $25,410.00. Following the transaction, the insider now owns 1,015,188 shares in the company, valued at $30,455,640. The trade was a 0.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 129,195 shares of company stock worth $3,581,772 over the last ninety days. Corporate insiders own 29.20% of the company's stock.
About Enliven Therapeutics
(
Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
